Literature DB >> 16796708

Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura.

Z Tao1, K Anthony, Y Peng, H Choi, L Nolasco, L Rice, J L Moake, J-F Dong.   

Abstract

BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is associated with congenital and acquired deficiency of ADAMTS-13, a metalloprotease that cleaves von Willebrand factor (VWF) and reduces its adhesive activity. Mutations throughout the ADAMTS13 gene have been identified in congenital TTP patients, most of whom have initial episodes during infancy or in early childhood. PATIENTS AND METHODS: We report the case of an adult male who was diagnosed with idiopathic thrombocytopenic purpura at age 34, and with TTP 14 years later. The patient was compound heterozygous for an 18 bp in-frame deletion (C365del) in the disintegrin domain and a point mutation of R1060W in the seventh thrombospondin domain of the ADAMTS-13 gene.
CONCLUSIONS: In vitro studies found that C365del and R1060W severely impair ADAMTS-13 synthesis in transfected Hela cells, whereas the deletion mutant also failed to cleave VWF under static and flow conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16796708     DOI: 10.1111/j.1538-7836.2006.02098.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  14 in total

Review 1.  Inherited thrombotic thrombocytopenic purpura.

Authors:  Miriam Galbusera; Marina Noris; Giuseppe Remuzzi
Journal:  Haematologica       Date:  2009-02       Impact factor: 9.941

2.  Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome.

Authors:  Shuju Feng; Stephen J Eyler; Yuzhou Zhang; Tara Maga; Carla M Nester; Michael H Kroll; Richard J Smith; Vahid Afshar-Kharghan
Journal:  Blood       Date:  2013-07-11       Impact factor: 22.113

Review 3.  Thrombotic microangiopathies: multimers, metalloprotease, and beyond.

Authors:  Joel Moake
Journal:  Clin Transl Sci       Date:  2009-10       Impact factor: 4.689

4.  Cysteine residues in CUB-1 domain are critical for ADAMTS13 secretion and stability.

Authors:  Zhou Zhou; Hui-Chun Yeh; Hua Jing; Christina Wang; Zhenyin Tao; Huiwan Choi; Khatira Aboulfatova; Renhai Li; Jing-Fei Dong
Journal:  Thromb Haemost       Date:  2010-09-30       Impact factor: 5.249

Review 5.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

Review 6.  Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.

Authors:  Chantal Loirat; Jean-Pierre Girma; Céline Desconclois; Paul Coppo; Agnès Veyradier
Journal:  Pediatr Nephrol       Date:  2008-06-24       Impact factor: 3.714

Review 7.  Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.

Authors:  Han-Mou Tsai
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

8.  Adult-onset congenital thrombotic thrombocytopenic purpura caused by a novel compound heterozygous mutation of the ADAMTS13 gene.

Authors:  Johannes G Krabbe; Evelien W M Kemna; Annuska L M Strunk; Pieter A Jobse; P A Kramer; L D Dikkeschei; L P W J van den Heuvel; Rob Fijnheer; Leo F Verdonck
Journal:  Int J Hematol       Date:  2015-08-13       Impact factor: 2.490

9.  The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura.

Authors:  Roberta Palla; Silvia Lavoretano; Rossana Lombardi; Isabella Garagiola; Mehran Karimi; Abdolreza Afrasiabi; Mani Ramzi; Raimondo De Cristofaro; Flora Peyvandi
Journal:  Haematologica       Date:  2008-12-30       Impact factor: 9.941

10.  ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment.

Authors:  Erica Rurali; Federica Banterla; Roberta Donadelli; Elena Bresin; Miriam Galbusera; Sara Gastoldi; Flora Peyvandi; Mary Underwood; Giuseppe Remuzzi; Marina Noris
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-04       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.